Moderna 2022 Priorities and Capital Allocation

The objective of our lead bivalent candidate (.214) is to demonstrate superior immunogenicity against variants of concern Three bivalents have been evaluated to date (containing an equal mass ratio) Primary focus has been on the bivalent approach - - mRNA-1273.211 (9 mutations, based on wild-type and Beta) mRNA-1273.213 (11 mutations, based on Beta and Delta) - mRNA-1273.214 (32 mutations, based on wild-type and Omicron) Our latest bivalent (.214) remains our lead candidate for fall 2022 NH booster · Objective of modified boosters is to demonstrate superior immunogenicity against VOC when compared to approved booster (1273 at 50 µg), while maintaining non-inferior protection against ancestral strains Slide 16 moderna

View entire presentation